NID2

Across TCGA pan-cancer cohorts, NID2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated NID2 data layer compared with 27 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher NID2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated NID2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

CCRCC, LUAD, and LSCC are the cancer types where NID2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	III,IV	0.752	0.341	.001	19	view →
LUAD	OS	Quartile	All	0.913	1.000	.006	17	view →
LSCC	DFS	Tertile	II,III,IV	0.798	1.000	.005	16	view →
GBM	OS	Median	All	0.526	0.285	.027	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

NID2–CCRCC (DFS)

Open the CCRCC breakdown →